Jim. you, Thank
vobramitamab study walk of product from candidates disclosure including with each has We our the I key continue promise, through patients prostate to safety and in believe our of you will great metastatic of proprietary TAMARACK and efficacy pipeline castration-resistant duocarmazine of new data programs, cancer.
immune our family a expression BX-HX. or ADC tumors cytotoxic regulation. broad We take a BX BX-HX across advantage multiple involved of solid designed antigen's vobra designed to Vobra duo cover this so tumor deliver have duo expressing types. member jump is in payload let's of the duocarmazine to today, duocarmycin lots DNA-alkylating to is in.
Vobramitamab of to molecules
recently BX-HX has few targeted up the form where are earlier release, patients earnings or an target.
The Investor which agents. X.X today's as link mg per the free updated to other TAMARACK provided the cut-off under consent interim taxane to we is X androgen set document know, data of ahead radiographic The not expanded sharing received XXX to rPFS is of the to vobra arms enrolled we original this survival, across receptor As population than will to download the informed the ideal regimen experimental direct primary the slide find have mentioned X, fully no or highlights generated previously our data, XXX of you vobra Slide we you safety all and progression-free although attributes agents arm X that patient in X Events duo. press being never section and with basis in for the believe on in kg Relations and today. per press either of a on weeks the patients an in the counted data set who patients Feel This study's completed the total less X XXX ARAT the we were can study based from X chemotherapy is in thus website of conducted access and or data you control mg the Presentations process. cancer is XX, page release.
Flip but an X you note kg of TAMARACK a a receive evaluate are date XXXX, with prior containing mCRPC April or patients endpoint.
We patients, study as every designed an of duo
is per slide, several I'll by on dosing are roughly disease mg X.X point measure. kg and measurable, see the cohort balanced there subjective of with a that As despite well patients over whereas arm out status split as exception with ECOG you favors number lesions PSA of cohort. very arms per X kg randomization, valuable this in ECOG XX-XX X broken kg characteristics. in not that slightly mg out X.X the patients can X we've baseline Both was than in X. provides fairly baseline ECOG cohort.
Slide Keep the mg the fewer target the and mind this per measurable a
terms study that had of you receptor a In agents versus androgen cohorts. to across having can a have recall to patients close taxane see, And XX-XX the both Also a had targeted prior one. more as split access for entry. was than prior few not, those mCRPC
post-baseline had all On X at the measurement. of Next, at show at X, ml let's Slide patients, subjects for X responses PSA duo dose received baseline least nanograms per PSA we who PSAXX least greater biological a XXX vobra activity. had which review represents and X than
For dosing XX% PSA patients while the greater XX.X% confirmed the than a their cohort, of patients kg per X evaluable a experienced PSA of in reduction reduction. XX had greater XX% XX% mg than
In out their with dosing Happily, XX% a while before commenced. the cohort, aligned experienced well reduction the patients PSA XX.X% expectations greater a PSAXX evaluable XX% X.X had confirmed of per mg generally are kg we the laid reduction. PSA PSAXX in results XX study than than these XX.X% of patients greater
with objective target XX.X% summarized XX responses as complete responses stable plus by XX.X%. patients X X on per in rate the as XX kg control dosing by measurements Slide among disease, of lesion measured or confirmed of summary the mg to baseline X the as partial complete some and partial responses Turning confirmed and disease response the or some and while achieved measured of cohort,
kg the unconfirmed was and of unconfirmed XX.X%. confirmed the CRs the in CRs, XX.X%.
Among ORR and unconfirmed cohort, dosing control measurements lesion The target ORR of mg disease XX% PRs, the and With per rate XX ORR X.X was unconfirmed inclusion PRs XX.X%. was the the with baseline inclusion patients with was the
PSA mg waterfall for the review plot Let's Slide shows next. the X per X kg waterfall the plot PSA cohort.
XX% the BX-HX appear It of data BX-HX XX.X% there see, scores based in required the therapy XX of XX greater plot. decrease response. patients as the had not biopsy does XX these or of on a XX.X% of expression patients remained achieving can archival H As that the confirmed a PSA. reducing Also shown cutoff. membrane or PSAXX XX for on on with thresholds these patients PSA you or are
this data. BX-HX At X for biomarker this mg X.X the will kg point, required.
Slide the still waterfall not is that implication likely interim per reviewing be diagnostic are cohort. shows plot We the PSA
Here, had a XX XX patients XX with a response. in of patients the XX% greater PSA these or or confirmed PSAXX of decrease achieving XX.X%
XX.X% patients data of patients therapy. on remained As of or cutoff, the XX
disease, X investigator-assessed review tumor cohort, shows which with plots. will of patients XX have the a mg X per I post-baseline size XX, did not On assessment. Slide the Next, kg measurable tumor waterfall
XX.X%, patients tumor X for X.X this all having a kg The disease stable while the earlier, ORR was mentioned with ORR XX.X%.
Slide confirmed I response was control for per response the partial disease. shows cohort. mg XX but XX.X%, was unconfirmed group rate either the As or
the confirmed ORR The XX%, XX.X%. assessment. of not ORR with the measurable was rate was post-baseline XX.X%. disease disease, patients was Here tumor have The did a this X for XX group while unconfirmed control
Next, duo Slide for the mCRPC I convey will of response, in X tumor a review the mg the for kg swimmer the which plot per XX of results the setting. vobra interim shows durability cohort. sense will hopefully
XX these cohort, is mg unconfirmed the patients with Here tumor XX% responses, of patients, ORR confirmed the cutoff. unconfirmed of per responses remained as with on had data X of or as shown that is therapy the on XX.X% patients the X data response the patients therapy XX.X%. XX.X% confirmed XX of XX evaluable cutoff.
In X were XX, XX.X% of the you or dosing unconfirmed responses, still XX the responses see of objective the the X XX or had unconfirmed ORR kg or the can inclusion XX.X%. X.X on Slide
treatment grade. and study any mg patients point leading TAMARACK Next, I data Grade treatment-emergent XX X.X or of on mg experienced Grade X and or at X safety patients an at Of received parameters XX data or Grade. a and as a had Of a study to which duo vobra fatal by or cohort, who classified kg mg events shows events patients greater per noted cohort. the of XX still Slide X summary X X cases in cohort, study drug the kg, X date. a XX date, adverse X.X related, myocardial XX.X% a infarction, at related the X XX Grade patients a greater dosing of adverse dosing XX, the XX.X% as which Slide kg, occurred XX.X% overall not or of adverse XX to event experienced cardiac mg-per-kg as of or per as acute TEAE XX in review of who discontinuation. to treatment study events X of TEAE initially XX.X% the are X of occurred fatal which the study being few classified patients pneumonitis, duo events not or XXX% X XX cut-off any discontinuation.
Also, per interim or investigated XX.X% TEAE of had this dosing in as total as Grade the an out follows: treatment assessed possibly related. XX receive at patients included leading vobra cutoff. I'll as the AE in will X the events was drug and occurred arrest,
mg per patient died. cohort X and a a had dosing X.X subsequently grade on addition, fusion plural In kg
on equal specific In shown treatment-emergent adverse to incidents terms than or those XX% XX. as of with greater Slide events,
of cohort For were dosing and XX.X%, note, X cohort X of palmar-plantar the of There of Grade this cohort Grade incidence or the pleural X asthenia, appetite incidence the of in Grade or X X.X%. nausea mg-per-kg no effusion in X.X%. any X X.X%. X included edema, effusion. peripheral XX.X% events. Grade and TEAEs X in in X Grade cohort, cohort common syndrome was Grade erythrodysesthesia palmar-plantar XX.X%, decreased and Grade X a pleural X.X%. most X decreased incidence nausea, of was this X X.X% this Grade The edema, cohort and the Of of dosing peripheral asthenia, of Grade of of incidence the the of in of Grade this grade of mg-per-kg TEAEs greater Grade any included were dosing was fatigue. pleural cohort and Of syndrome events.
Also, in X erythrodysesthesia XX.X% There no X.X this effusion of Grade Also, X X.X% and appetite, of greater with note, X most of common X the Grade
being to equal goal as are As in Slide believe and XXXX saw of data represented at severity effects overwhelmingly are activity cutoff than the butterfly of with very pleased we of of effusion the that off with visually and the either Overall, palmar-plantar with dose TEAEs XX, of the of well success April the onset we achieved manageable. interim these the are limited our with to the the data data or side that are greater the Also, study tolerable laid parameters in cut reducing comparison on we expansion I X both aligned Phase of biological what study.
We doses Grade recent of in we the erythrodysesthesia incidence to as X. XX, plot the most study. observed XX% all out in pleural or
X endpoint, either as undertaking of in the or for radiographic to mg initial XXXX. We consider the steps will mCRPC data, survival we evaluate Phase are III per rPFS, study selection primary that the kg.
To or X.X dose the prepare initiation including of future of study's end, we potential necessary currently the in progression-free continue a to totality
plan tumor additional of we cancer, lung call, safety, share cutoff.
Also, cancer, head expand and on ahead, durability earnings lung in types to cell as prior squamous including carcinoma plan trial the data, being XXXX future we with Looking neck cell the cell enroll evaluated to second of non-small a rPFS to the mentioned half TAMARACK updated on data efficacy and the expect and cancer. based in and our anal small melanoma, patients TAMARACK
other X that molecules BX-HX. target mid-XXXX.
Recall, initiate dosing to that have expect these cohorts we clinical additional in We in
first, The novel licensed payload, Synaffix. investigational based SYNtecan is E, topoisomerase inhibitor linker which from ADC MGCXXX a incorporating X we an
readily greater both Our incorporates next.
MGCXXX a Fc-optimized and validated linker enoblituzumab, these through that second the recently cancer antibodies potent additional an technology. Association monoclonal ADCs. other walk is hydro BX-HX-directed deruxitecan BX-HX Synaffix' targeted to based molecules MGCXXX molecule or space was to with conjugated on investigational topoisomerase-based the at [indiscernible] Research Cancer was of you antibody. potency payload Annual clinically MGCXXX presented payload I'll shown American in In have studies, combines exatecan preclinical Meeting. data for preclinical a DXd, than utilized
has than toxicology well to shown DXd tested. in dose the our mechanisms less to SN-XX. addition, In payload show levels MGCXXX MGCXXX conducted be tolerated was multidrug-resistant and cynomologous susceptible study all that been monkeys Also, at
complementary development. predictable to in escalation conducive displayed domain the models duo approximate dose vobra The tested, a MGCXXX the proportion the targeting We MGCXXX. variable Phase molecule dose view of pharmacokinetics BX-HX. for initiated We for recently MGCXXX as BX-HX Finally, duo. study of I animal is of in vobra to of indicating a behavior further same sequence targeting MGCXXX approach contained clinical
strategy X valuable potentially with believe our and clinical potential cancers, we tool as or tumor remain the different the our pathway repertoire. vobra an another confident mechanisms or viewing distinct stages having BX-HX agents ultimate inhibitor in action specifically, in used of duo address Topo their More may of enhance therapeutic in combination that be targeting with to one MGCXXX utility.
We additional
MRI scan an are to intense evaluating translationally as with optional academic radical XXX molecule study investigator-sponsored CT and patients bone conventional with this a activity prostate preferences. high-risk investigator-sponsored, prior our enoblituzumab given of men is patients and and per II imaging, PSMA study to enoblituzumab, localized and cancer. prostate in randomized in collaborators pretreatment as Phase including neoadjuvant the PET well of up cancer.
The prostate prostatectomy biopsy prostate as enrolling Regarding institutional will Eligible undergo HEAT
lymphocytes, to most on We cells, the you expressing designed have tumor which Next, such infiltrating abundant tumor PD-X our dual preferential as tetravalent in x are molecule. CTLA-X PD-X microenvironment. update lorigerlimab, bispecific DART blockade I'll on lorigerlimab CTLA-X
provide and data study. of first treated a in XXX of randomized LORIKEET randomized enrollment study clinical in A mCRPC lorigerlimab current are We the half the combination this in second-line trial primary endpoint docetaxel docetaxel the enrolling II The study LORIKEET of the of XXXX. with clinical Phase be expect completing study versus are year includes X:X to the design planned chemotherapy-naive rPFS. patients alone We study patients. anticipate of update total in to a
enroll dose I/II in and XXXX. additional combination in in escalation X the of duo at patients continue lorigerlimab study tumors. In anticipate solid commencing patients expansion study of indication addition, to in with Phase with a combination mCRPC this vobra advanced we We least in dose
our up, x antitumor dosing the next-generation and CDXXX longer to is syndrome bispecific minimize permitting MGDXXX through Next intermittent that DART CDX half-life. a cytokine incorporates component activity designed release maintaining cytolytic molecule CDX while
escalation study including leukemia to and MGDXXX the study. during has is and ongoing option Gilead that Phase license refractory points decision I in positive predefined myelodysplastic dose patients Phase or Our malignancies, the myeloid I with syndromes. of CDXXX acute hematologic MGDXXX Recall relapsed
of ADC in in cancers, antibody. ADAMX specific In cancer proteins preclinical at carcinoma type is X studies, expressed pancreatic, April. topoisomerase representing lung, projects, the payload over colorectal, treatment.
We an incorporating attractive and preclinical ADAMX MGCXXX member and gastric, of Annual MGCXXX and for is In second neck it MGCXXX small genesis family activity the role an that a of presented in terms cholangiocarcinoma. multifunctional tumor antitumor the Synaffix progression novel cancer recently is our Adams and transmembrane preclinical making target data multiple Meeting vivo and in a cell targeting play inhibitor-based demonstrated head linker a AACR models X
is inhibitor preclinical tolerated In mild addition, MGCXXX and solid ocular which as the based option ADAMX tumors. offered of treating a with concern investigation therapeutic tubulin a a study, for results MGCXXX effects dose levels at nonhuman in ADCs.
These promising no high reversible side with primate continued was support well toxicity
MGCXXX by for this We the are or currently new anticipating, drug investigational end submitting year. application IND of an
look clinical calls. additional on more To future life-changing the as for MacroGenics believe as to we to forward the and has MGCXXX, to about support financial are development open conclude, molecules molecules call delivering telling vision would additional IND our be We now and future medicines to developing potential expertise resources happy we well you questions. I exploring submission. patients. Beyond cancer of technical these for
